{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"13"}]}],"title":"Complete response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}],"title":"Partial response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}],"title":"Stable disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"title":"Progression"}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"description":"The number of participants for this outcome measure is 25 participants with baseline characteristics and response evaluation. Since this was a retrospective study, response criteria were not defined. Response determinations as recorded in the medical record by the treating physician were abstracted on each participant for data analysis. Response rates will be reported with 95% confidence intervals (binomial distribution). Descriptive statistics will be used to summarize baseline clinical, histological, and viral characteristics.","groups":[{"description":"8 participants with survival less than 2 years","id":"OG000","title":"Survival Less Than 2 Years"},{"description":"17 participants with survival more than or equal to 2 years","id":"OG001","title":"Survival More Than or Equal to 2 Years"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Response rates for the first line of therapy were estimated by survival status.","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Response Rates","type":"PRIMARY","unitOfMeasure":"Participants"}